MeSH tree: C12.200.777.419.473.160
For patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of about 57 months, according to a study presented at the ...
Feb 1, 2024
0
40
Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large ...
Jan 29, 2024
0
40
For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.
Jan 27, 2024
0
60
A new study led by Yale Cancer Center researchers at Yale School of Medicine has revealed a significant increase in patients starting immunotherapy within one month of death. Using a national clinical database, the researchers ...
Jan 4, 2024
0
75
Oscoda, Michigan, has the distinction as the first community where "forever chemicals" were found seeping from a military installation into the surrounding community. Beginning in 2010, state officials and later residents ...
Dec 27, 2023
0
78
It's no secret that a high-fiber diet is good for you—just ask Google. Lots of research suggests that eating a high-fiber diet can lower your risk for certain cancers, but less is known about whether fiber can also help you ...
Dec 13, 2023
0
56
A study by the University of the Basque Country (UPV/EHU) uses game theory to establish that tumors with less cellular heterogeneity are more aggressive
Dec 4, 2023
0
31
Greater adherence to the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations—which encourage a healthy lifestyle—is associated with a lower risk of all cancers combined ...
Nov 27, 2023
0
41
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic ...
Oct 22, 2023
0
70
A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus ...
Oct 21, 2023
0
144
